Literature DB >> 29546493

Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.

Massimo Galia1, Francesco Agnello2, Gianvincenzo Sparacia1, Domenica Matranga3, Domenico Albano1, Massimo Midiri1, Roberto Lagalla1.   

Abstract

PURPOSE: To retrospectively analyze the evolution of indeterminate hepatocellular nodules in cirrhotic patients on serial Gd-EOB-DPTA-enhanced MRI, and to identify predictors of HCC development.
MATERIALS AND METHODS: This IRB approved study included 33 cirrhotic patients with 69 indeterminate hepatocellular nodules (mean diameter 1.1 cm) at baseline Gd-EOB-DPTA-enhanced MRI and a Gd-EOB-DPTA-enhanced-MRI follow-up of at least 2 years. Two radiologists evaluated size and signal intensity of each nodule at baseline and follow-up. Age, cirrhosis etiology, and HCC history were recorded. Data were compared between nodules that became HCCs at follow-up (HCC) and those that did not (no-HCC).
RESULTS: On follow-up, 5/69 nodules became HCCs and 64/69 showed indeterminate characteristics. HCC history was more frequently found in HCCs than in no-HCCs. Age, sex, and cirrhosis etiology were not significantly different between HCCs and no-HCCs. HCCs had a significantly greater baseline diameter and increase in size than no-HCCs. Hepatobiliary phase hypointensity was significantly more common in HCCs than in no-HCCs. Multivariate regression analysis showed that increase in size (OR 10.48; sensitivity, 100%; specificity, 81.2%; p < 0.001) and hepatobiliary phase hypointensity (OR 1.02; sensitivity, 100%; specificity, 78.1%; p < 0.001) was associated with HCC development.
CONCLUSION: Indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients rarely became HCCs. Hepatobiliary phase hypointensity had a weak association with HCC development.

Entities:  

Keywords:  Cirrhosis; Gd-EOB-DTPA; HCC; Indeterminate hepatocellular nodule; Liver MRI

Mesh:

Substances:

Year:  2018        PMID: 29546493     DOI: 10.1007/s11547-018-0873-8

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  30 in total

1.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.

Authors:  Jorge A Marrero; Hero K Hussain; Hahn V Nghiem; Ramsey Umar; Robert J Fontana; Anna S Lok
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

2.  Outcomes of dysplastic nodules in human cirrhotic liver: a clinicopathological study.

Authors:  S Seki; H Sakaguchi; T Kitada; A Tamori; T Takeda; N Kawada; D Habu; K Nakatani; S Nishiguchi; S Shiomi
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

3.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

4.  Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.

Authors:  Young Joo Suh; Myeong-Jin Kim; Jin-Young Choi; Young Nyun Park; Mi-Suk Park; Ki Whang Kim
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

5.  Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma.

Authors:  Tae Kyoung Kim; Kyoung Ho Lee; Hyun-Jung Jang; Masoom A Haider; Lindsay M Jacks; Ravi J Menezes; Seong Ho Park; Leyla Yazdi; Morris Sherman; Korosh Khalili
Journal:  Radiology       Date:  2011-03-01       Impact factor: 11.105

6.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

7.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

8.  Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival.

Authors:  L Barbara; G Benzi; S Gaiani; F Fusconi; G Zironi; S Siringo; A Rigamonti; C Barbara; W Grigioni; A Mazziotti
Journal:  Hepatology       Date:  1992-07       Impact factor: 17.425

9.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  2 in total

Review 1.  Hepatic tumors: pitfall in diagnostic imaging.

Authors:  Giulia Grazzini; Diletta Cozzi; Federica Flammia; Roberta Grassi; Andrea Agostini; Maria Paola Belfiore; Alessandra Borgheresi; Maria Antonietta Mazzei; Chiara Floridi; Gianpaolo Carrafiello; Andrea Giovagnoni; Silvia Pradella; Vittorio Miele
Journal:  Acta Biomed       Date:  2020-07-13

2.  Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases.

Authors:  Vincenza Granata; Roberta Fusco; Francesca Maio; Antonio Avallone; Guglielmo Nasti; Raffaele Palaia; Vittorio Albino; Roberto Grassi; Francesco Izzo; Antonella Petrillo
Journal:  Infect Agent Cancer       Date:  2019-11-27       Impact factor: 2.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.